Try our beta test site
145 studies found for:    Hemophilia: Clinical Trials
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)
Condition: Hemophilia A
Intervention: Drug: Emicizumab
2 Completed Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: nonacog beta pegol
3 Completed Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: nonacog beta pegol
4 Active, not recruiting A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
5 Active, not recruiting A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BAY94-9027
6 Active, not recruiting Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
Condition: Hemophilia B
Intervention: Genetic: AAV5-hFIX
7 Recruiting A Study of Once-Weekly Emicizumab in Children and Adolescents With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)
Condition: Hemophilia A
Intervention: Drug: Emicizumab
8 Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial
Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
9 Completed Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
10 Recruiting A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients With Inhibitors (HAVEN 1)
Condition: Hemophilia A
Intervention: Drug: Emicizumab
11 Completed A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
12 Completed Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
13 Recruiting A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Interventions: Drug: N9-GP;   Drug: ALPROLIX®
14 Completed
Has Results
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: rFVIII (BAY81-8973) on demand;   Biological: rFVIII (BAY81-8973) prophylaxis low-dose;   Biological: rFVIII (BAY81-8973) prophylaxis high-dose
15 Completed A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
16 Completed Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: Concizumab;   Drug: placebo
17 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
18 Completed
Has Results
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: vatreptacog alfa (activated);   Drug: eptacog alfa (activated)
19 Terminated A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Healthy
Intervention: Drug: NNC172-2021
20 Completed Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.